Zydelig (idelalisib)

News alerts, weekly reports and conference planners

Company:

Gilead

Drug class:

PI3Kδ inhibitor

Related drugs:

No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: B - Late Trials rituximab + idelalisib Sensitive : B	rituximab + idelalisib Sensitive: B - Late Trials rituximab + idelalisib Sensitive : B
TCF3-PBX1 fusion	B Acute Lymphoblastic Leukemia	TCF3-PBX1 fusion	B Acute Lymphoblastic Leukemia	idelalisib Sensitive: C3 – Early Trials idelalisib Sensitive : C3	idelalisib Sensitive: C3 – Early Trials idelalisib Sensitive : C3
TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	TP53 T175H + PIK3CA H1047R	Burkitt Lymphoma	idelalisib Sensitive: C4 – Case Studies idelalisib Sensitive : C4	idelalisib Sensitive: C4 – Case Studies idelalisib Sensitive : C4
TP53 mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	idelalisib Sensitive: D – Preclinical idelalisib Sensitive : D	idelalisib Sensitive: D – Preclinical idelalisib Sensitive : D
Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	idelalisib Resistant: D – Preclinical idelalisib Resistant : D	idelalisib Resistant: D – Preclinical idelalisib Resistant : D
ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	idelalisib Resistant: D – Preclinical idelalisib Resistant : D	idelalisib Resistant: D – Preclinical idelalisib Resistant : D
MAP2K1 overexpression	Chronic Lymphocytic Leukemia	MAP2K1 overexpression	Chronic Lymphocytic Leukemia	idelalisib Resistant: D – Preclinical idelalisib Resistant : D	idelalisib Resistant: D – Preclinical idelalisib Resistant : D
CD69 overexpression	Chronic Lymphocytic Leukemia	CD69 overexpression	Chronic Lymphocytic Leukemia	ibrutinib + idelalisib Sensitive: D – Preclinical ibrutinib + idelalisib Sensitive : D	ibrutinib + idelalisib Sensitive: D – Preclinical ibrutinib + idelalisib Sensitive : D

Zydelig (idelalisib)

Associations
(29)

Associations
(29)

Zydelig (idelalisib)

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)